UNSPSC 51161572: Nivimedone sodium anhydrous

This classification denotes a mast cell stabilizer with the molecular formula C11H8NO4.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 50HX07BAJU, chemically known as 1h-indene-1,3(2h)-dione, 5,6-dimethyl-2-nitro-, ion(1-), sodium (1:1), but more generally known as nivimedone sodium anhydrous, which bears US NIH Compound Identifier 64752. European Medicines Agency schedules nivimedone sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09333MIG.

Most nations, for tariff purposes, schedule nivimedone sodium anhydrous under HS 29147000. SMILES: CC1CC2C(CC1C)C(=O)C(=[N+]([O-])[O-])C2=O.[NA+].

UNSPSC 51161572 Nivimedone sodium anhydrous is a Commodity code covering pharmaceutical active pharmaceutical ingredients and finished drugs. State and local governments procure under this code primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and their facility networks—including hospitals, clinics, correctional facilities, and other state and local healthcare operations—to secure volume pricing on generic and branded pharmaceuticals, over-the-counter products, and specialty medications. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for recent activity, consolidating procurement across multiple states including Oregon and other participating members. Vendors must demonstrate current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and robust insurance coverage including commercial general liability of at least $5,000,000 per occurrence.

MMCAP issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. Awarded vendors will begin supplying products through authorized wholesalers by July 1, 2026, under a two-year initial contract term with optional extensions at MMCAP's discretion. Evaluation weighting emphasizes price competitiveness (75 percent), with lesser weight on fixed pricing (10 percent), EDI capability (5 percent), administrative fee compliance (5 percent), and administrative format requirements (5 percent). All products must be available in the marketplace by May 15, 2026, maintain expiration dates of at least one year from manufacture with a minimum six-month shelf life, and comply with FDA requirements. Vendors should anticipate a 3 percent administrative fee on all contract purchases and performance penalties of $200 to $1,500 per violation for issues including late reporting, missed onboarding timelines, or improper class-of-trade denials.